EA201190337A1 - Способ лечения - Google Patents
Способ леченияInfo
- Publication number
- EA201190337A1 EA201190337A1 EA201190337A EA201190337A EA201190337A1 EA 201190337 A1 EA201190337 A1 EA 201190337A1 EA 201190337 A EA201190337 A EA 201190337A EA 201190337 A EA201190337 A EA 201190337A EA 201190337 A1 EA201190337 A1 EA 201190337A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- solvates
- patient
- methods
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Изобретение относится к способам лечения возрастной макулярной дегенерации у пациента путем введения пазопаниба или его фармацевтически приемлемых солей или сольватов.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22611309P | 2009-07-16 | 2009-07-16 | |
PCT/US2010/042211 WO2011009016A1 (en) | 2009-07-16 | 2010-07-16 | Treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201190337A1 true EA201190337A1 (ru) | 2012-06-29 |
Family
ID=43449814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201190337A EA201190337A1 (ru) | 2009-07-16 | 2010-07-16 | Способ лечения |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120165354A1 (ru) |
EP (1) | EP2453748A4 (ru) |
JP (1) | JP2012533562A (ru) |
KR (1) | KR20120049267A (ru) |
CN (1) | CN102573477A (ru) |
AU (1) | AU2010273254A1 (ru) |
BR (1) | BR112012001030A2 (ru) |
CA (1) | CA2768237A1 (ru) |
EA (1) | EA201190337A1 (ru) |
IL (1) | IL217492A0 (ru) |
MX (1) | MX2012000706A (ru) |
SG (1) | SG178032A1 (ru) |
WO (1) | WO2011009016A1 (ru) |
ZA (1) | ZA201109517B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201201808A (en) * | 2010-01-06 | 2012-01-16 | Glaxo Wellcome Mfg Pte Ltd | Treatment method |
AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
US20140235678A1 (en) | 2011-06-28 | 2014-08-21 | Bayer Healthcare Llc | Topical Ophthalmological Pharmaceutical Composition containing Sorafenib |
JP5998213B2 (ja) | 2011-06-28 | 2016-09-28 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | レゴラフェニブを含有する眼科用局所医薬組成物 |
CA2876311A1 (en) | 2012-06-25 | 2013-12-19 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing sunitinib |
UY35183A (es) | 2012-12-21 | 2014-07-31 | Bayer Healthcare Llc | Composición farmacéutica oftalmológica tópica que contiene regorafenib |
DK3039424T3 (da) | 2013-08-28 | 2020-08-31 | Crown Bioscience Inc Taicang | Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse |
US10360673B2 (en) | 2015-03-26 | 2019-07-23 | Eyekor, Llc | Image analysis |
CN105800652B (zh) * | 2016-02-06 | 2017-08-25 | 杭州锦江集团有限公司 | 低铝硅比铝土矿的干法烧成方法 |
CN112730725A (zh) * | 2019-10-28 | 2021-04-30 | 齐鲁制药有限公司 | 一种测定盐酸培唑帕尼中氯离子含量的分析方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088579B2 (en) * | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
EP1941061A1 (en) * | 2005-11-02 | 2008-07-09 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Method evolved for recognition and testing of age related macular degeneration (mert-armd) |
US20080293691A1 (en) * | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
CA2659392A1 (en) * | 2006-07-13 | 2008-01-17 | University Of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
US20090263801A1 (en) * | 2008-01-04 | 2009-10-22 | Duke University | Phenotype-Genotype Relationship in Age-Related Macular Degeneration |
-
2010
- 2010-07-16 CN CN201080033244XA patent/CN102573477A/zh active Pending
- 2010-07-16 CA CA2768237A patent/CA2768237A1/en not_active Abandoned
- 2010-07-16 MX MX2012000706A patent/MX2012000706A/es unknown
- 2010-07-16 EP EP10800585A patent/EP2453748A4/en not_active Withdrawn
- 2010-07-16 WO PCT/US2010/042211 patent/WO2011009016A1/en active Application Filing
- 2010-07-16 JP JP2012520806A patent/JP2012533562A/ja active Pending
- 2010-07-16 US US13/383,935 patent/US20120165354A1/en not_active Abandoned
- 2010-07-16 KR KR1020127003960A patent/KR20120049267A/ko not_active Application Discontinuation
- 2010-07-16 SG SG2012002895A patent/SG178032A1/en unknown
- 2010-07-16 BR BR112012001030A patent/BR112012001030A2/pt not_active IP Right Cessation
- 2010-07-16 AU AU2010273254A patent/AU2010273254A1/en not_active Abandoned
- 2010-07-16 EA EA201190337A patent/EA201190337A1/ru unknown
-
2011
- 2011-12-22 ZA ZA2011/09517A patent/ZA201109517B/en unknown
-
2012
- 2012-01-12 IL IL217492A patent/IL217492A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2012533562A (ja) | 2012-12-27 |
KR20120049267A (ko) | 2012-05-16 |
US20120165354A1 (en) | 2012-06-28 |
CA2768237A1 (en) | 2011-01-20 |
WO2011009016A1 (en) | 2011-01-20 |
BR112012001030A2 (pt) | 2019-09-24 |
MX2012000706A (es) | 2012-06-01 |
IL217492A0 (en) | 2012-02-29 |
ZA201109517B (en) | 2013-05-29 |
SG178032A1 (en) | 2012-03-29 |
CN102573477A (zh) | 2012-07-11 |
EP2453748A1 (en) | 2012-05-23 |
EP2453748A4 (en) | 2013-01-02 |
AU2010273254A1 (en) | 2012-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201190337A1 (ru) | Способ лечения | |
EA201290603A1 (ru) | Способ лечения | |
BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
TN2013000275A1 (en) | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) | |
MX363243B (es) | Composiciones para tratar cáncer y usos de dichas composiciones. | |
UA111841C2 (uk) | Сполуки бензотіазолу та їх фармацевтичне застосування | |
NI201000105A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada. | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
UA113627C2 (xx) | Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
EA201490269A1 (ru) | Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета | |
IN2014CN04634A (ru) | ||
MX2014005209A (es) | Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas. | |
MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
EA201200428A1 (ru) | Композиция и способ для лечения ожирения | |
EA201690327A1 (ru) | Терапевтические способы | |
FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
NZ598490A (en) | Treatment of macular degeneration | |
PH12014502065A1 (en) | Vesicular formulations | |
MX2013007055A (es) | Derivados de sanglifehrina y metodos para su produccion. | |
IN2014DN03010A (ru) | ||
TW200744627A (en) | Methods for the treatment of macular degeneration and related eye conditions | |
MX2014000870A (es) | Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina. |